TY - JOUR
T1 - Treatment of venous thrombosis at unusual sites
AU - McBane, Robert D.
AU - Wysokinski, Waldemar E.
PY - 2008/4
Y1 - 2008/4
N2 - The literature is filled with randomized controlled trial data to guide most steps in managing patients with deep venous thrombosis of the extremities or pulmonary embolism. Venous thrombosis, however, is not limited to these locations and may involve the cerebral venous sinuses, renal veins, splanchnic veins, and ovarian veins. The causes of these thrombi are often unique to the venous segments involved and typically stem from pathologies of the organs supplied by these veins. Very little randomized controlled trial data exist to guide therapy for these atypical venous thrombi. Treatment should focus on correcting the underlying disease and relieving venous congestion of the involved organ while preserving organ functionality. Although natural history data are limited, recurrence rates for these atypical venous thrombi appear to be relatively low. Indefinite secondary anticoagulant prophylaxis is therefore primarily dictated by the congenital or acquired pathology precipitating the event.
AB - The literature is filled with randomized controlled trial data to guide most steps in managing patients with deep venous thrombosis of the extremities or pulmonary embolism. Venous thrombosis, however, is not limited to these locations and may involve the cerebral venous sinuses, renal veins, splanchnic veins, and ovarian veins. The causes of these thrombi are often unique to the venous segments involved and typically stem from pathologies of the organs supplied by these veins. Very little randomized controlled trial data exist to guide therapy for these atypical venous thrombi. Treatment should focus on correcting the underlying disease and relieving venous congestion of the involved organ while preserving organ functionality. Although natural history data are limited, recurrence rates for these atypical venous thrombi appear to be relatively low. Indefinite secondary anticoagulant prophylaxis is therefore primarily dictated by the congenital or acquired pathology precipitating the event.
UR - http://www.scopus.com/inward/record.url?scp=41749088698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41749088698&partnerID=8YFLogxK
U2 - 10.1007/s11936-008-0015-z
DO - 10.1007/s11936-008-0015-z
M3 - Review article
C2 - 18325316
AN - SCOPUS:41749088698
SN - 1092-8464
VL - 10
SP - 136
EP - 145
JO - Current Treatment Options in Cardiovascular Medicine
JF - Current Treatment Options in Cardiovascular Medicine
IS - 2
ER -